Winnergy Medical Public Company (WINMED) Fair Value & Analysis
Healthcare · TH · Market cap 332M THB
Fair value as of: Jul 11, 2026
From 14 valuation models · updated 30 days ago
Share price +10.8% over the past month.
Below-average quality, currently priced close to our fair value.
What matters now
- The price sits above even our optimistic bull case (0.8600 THB). The favourable scenario is already priced in.
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 11, 2026.
How to read this chart
60‑month range 0.7400 THB – 7.46 THB · fair‑value band 0.6300 THB – 0.8600 THB · the 0.9200 THB price screens above the 0.8300 THB fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 11, 2026.
Analysis
Winnergy Medical Public Company (WINMED) currently trades at 0.9200 THB, while our model-based Fair Value estimate is 0.8300 THB, implying the stock looks roughly 9.8% fairly valued today. The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Winnergy Medical Public Company generated revenue of 647M THB at a net margin of 2.4%. Revenue declined 1.5% year over year. It earns a return on equity of 2.4%. Net debt stands at 343M THB. Fundamentals as of Jul 11, 2026
Our scenario range runs from 0.6300 THB (bear case) to 0.8600 THB (bull case); at 0.9200 THB, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 43% below its 52-week high and 35% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 2% fair-value upside, at -10%, WINMED screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 14 models by family
Widest divergence: Asset-Based (1.06 THB) versus Earnings-Based (0.1200 THB). Highest evidence: Residual Income (76).
Notify me when WINMED reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 11, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 37 · Market factors (momentum, volatility) 42
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Winnergy Medical Public Company Limited engages in the distribution of medical and diagnostic equipment in Thailand. The company imports and distributes technology and diagnostic kits for cervical cancer screening, including cytology examinations using automatic slide preparation machines and testing for human papilloma virus, and colposcopes.
Full company description
Winnergy Medical Public Company Limited engages in the distribution of medical and diagnostic equipment in Thailand. The company imports and distributes technology and diagnostic kits for cervical cancer screening, including cytology examinations using automatic slide preparation machines and testing for human papilloma virus, and colposcopes. It also offers equipment for testing blood quality and blood collection bags for blood donation; blood quality testing products; blood freezers; blood banking, including pathogen inactivation; blood bag tube sealer; blood donor chairs; instrument for counting the number of leukocytes residual in blood; and device used to cut and connect both dry and wet blood bags. In addition, the company sells mosquito trappers for outdoor and indoor use; and offers HPV and STI self-collect test kits under AVA name. The company was formerly known as Winnergy Medical Co., Ltd. and changed its name to Winnergy Medical Public Company Limited in September 2020. Winnergy Medical Public Company Limited was incorporated in 2004 and is headquartered in Bangkok, Thailand.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Winnergy Medical Public Company reported revenue of 647M THB in FY2025 versus 539M THB in FY2021, a compound +4.7%/yr. Reported net income was 15.2M THB in FY2025, compounding −30.5%/yr from FY2021.
Watch WINMED: get an alert when its fair value changes →
Peer Group
Medical Distribution · 81 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Distribution median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jul 11, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation MCK | $805.96 | $819.31 | +2% |
| Cencora, Inc COR | $303.44 | $175.74 | -42% |
| Cardinal Health, Inc CAH | $224.94 | $141.77 | -37% |
| Henry Schein, Inc HSIC | $87.82 | $74.67 | -15% |
| Shanghai Pharmaceuticals Holding 601607 | ¥16.70 | ¥33.96 | +103% |
| Sinopharm Group 1099 | HK$16.74 | HK$61.33 | +266% |
| Galenica AG GALE | CHF 87.05 | CHF 61.79 | -29% |
| Guangzhou Baiyunshan Pharmaceutical Holdings 600332 | ¥21.50 | ¥28.65 | +33% |
| Jointown Pharmaceutical Group 600998 | ¥4.99 | ¥9.84 | +97% |
| Asker Healthcare Group ASKER | kr 79.45 | kr 25.69 | -68% |
Compare Winnergy Medical Public Company with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Winnergy Medical Public Company (WINMED) overvalued or undervalued?
What is the fair value of WINMED?
What is the quality score of WINMED?
What is the revenue of Winnergy Medical Public Company (WINMED)?
What is the net profit margin of WINMED?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Winnergy Medical Public Company and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.